Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformations

Cardiology in the Young

Volumn 15, Issue 3, 2005, Pages 266-273

  Feltes, Timothy F ^a   Groothuis, Jessie R ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b Hollis Eden Pharmaceuticals Inc   (United States)

Author keywords

Asthma; Congestive heart failure; Palivizumab; Prophylaxis; Pulmonary oedema; Reactive airways disease

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); PALIVIZUMAB;

ARTICLE; ASTHMA; BRONCHUS OBSTRUCTION; CHILD; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; INFECTION PREVENTION; LUNG EDEMA; LUNG INFILTRATE; LYMPHATIC DRAINAGE; MICROVASCULATURE; MORBIDITY; NONHUMAN; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION;

HEART DEFECTS, CONGENITAL; HUMANS; INFANT; INFANT, NEWBORN; LUNG DISEASES; LUNG DISEASES, OBSTRUCTIVE; PULMONARY EDEMA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS;

EID: 25844503466     PISSN: 10479511     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1047951105000557     Document Type: Article

References (56)

1. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992; 121: 348-354.
2. Boyce TG, Mellen BG, Mitchel EF Jr, Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137: 865-870.
3. Simoes EA. Immunoprophylaxis of respiratory syncytial virus: global experience. Respir Res 2002; 3 (Suppl 1): S26-S33.
4. Khongphatthanayothin A, Wong PC, Samara Y, et al. Impact of respiratory syncytial virus infection on surgery for congenital heart disease: postoperative course and outcome. Crit Care Med 1999; 27: 1974-1981.
5. Inselman LS, Mellins RB. Growth and development of the lung. J Pediatr 1981; 98: 1-15.
6. Langston C. Normal and abnormal structural development of the human lung. Prog Clin Biol Res 1983; 140: 75-91.
7. Langston C, Kida K, Reed M, Thurlbeck WM. Human lung growth in late gestation and in the neonate. Am Rev Respir Dis 1984; 129: 607-613.
8. Hansen T, Corbet A. Pulmonary physiology of the newborn. In: Taeusch HW, Ballard RA (eds). Avery's Diseases of the Newborn. Elsevier Saunders, Philadelphia, 2005, pp 634-647.
9. Johnson RJ, Haworth SG. Pulmonary vascular and alveolar development in tetralogy of Fallot: a recommendation for early correction. Thorax 1982; 37: 893-901.
10. Guyton AC, Lindsey AW. Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of pulmonary edema. Circ Res 1959; 7: 649-657.
11. Feltes TF, Hansen TN. Effects of an aorticopulmonary shunt on lung fluid balance in the young lamb. Pediatr Res 1989; 26: 94-97.
12. West JB, Mathieu-Costello O. Structure, strength, failure and remodeling of the pulmonary blood-gas barrier. Annu Rev Physiol 1999; 61: 543-572.
13. Miserocchi G, Negrini D, Passi A, De Luca G. Development of lung edema: interstitial fluid dynamics and molecular structure. News Physiol Sci 2001; 16: 66-71.
14. Drake RE, Doursout MF. Pulmonary edema and elevated left atrial pressure: four hours and beyond. News Physiol Sci 2002; 17: 223-226.
15. West JB. Invited review: pulmonary capillary stress failure. J Appl Physiol 2000; 89: 2483-2489.
16. Fu Z, Heldt GP, West JB. Increased fragility of pulmonary capillaries in newborn rabbit. Am J Physiol Lung Cell Mol Physiol 2003; 284: L703-L709.
17. Kingsbury MP, Huang W, Donnelly JL, et al. Structural remodelling of lungs in chronic heart failure. Basic Res Cardiol 2003; 98: 295-303.
18. Patterson CE, Lum H. Update on pulmonary edema: the role and regulation of endothelial barrier function. Endothelium 2001; 8: 75-105.
19. Gorenflo M, Gross P, Bodey A, et al. Plasma endothelin-1 in patients with left-to-right shunt. Am Heart J 1995; 130: 537-542.
20. +-ATPase in rat type II pneumocytes. J Appl Physiol 1986; 60: 1584-1589.
21. Matthay MA, Folkesson HG, Clerici C. Lung epithelial fluid transport and the resolution of pulmonary edema. Physiol Rev 2002; 82: 569-600.
22. Guazzi M, Agostoni P, Guazzi MD. Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan in chronic heart failure. J Am Coll Cardiol 2001; 37: 398-406.
23. Drake R, Giesler M, Laine G, Gabel J, Hansen T. Effect of outflow pressure on lung lymph flow in unanesthetized sheep. J Appl Physiol 1985; 58: 70-76.
24. Johnson SA, Vander Straten MC, Parellada JA, Schnakenberg W, Gest AL. Thoracic duct function in fetal, newborn, and adult sheep. Lymphology 1996; 29: 50-56.
25. Feltes TF, Hansen TN. Pulmonary edema. In: Garson A Jr, Bricker T, Fisher DJ, Neish SR (eds). The Science and Practice of Pediatric Cardiology. Williams & Wilkins, Baltimore, 1998, pp 313-327.
26. von der Weid PY, Zhao J, Van Heiden DF. Nitric oxide decreases pacemaker activity in lymphatic vessels of guinea pig mesentery. Am J Physiol Heart Circ Physiol 2001; 280: H2707-H2716.
27. Griese M. Respiratory syncytial virus and pulmonary surfactant. Viral Immunol 2002; 15: 357-363.
28. Carpenter TC, Reeves JT, Durmowicz AG. Viral respiratory infection increases susceptibility of young rats to hypoxia-induced pulmonary edema. J App Physiol 1998; 84: 1048-1054.
29. Carpenter TC, Stenmark KR. Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis. Pediatr Infect Dis J 2004; 23 (Suppl): S33-S40.
30. Lee CG, Yoon HJ, Zhu Z, et al. Respiratory syncytial virus stimulation of vascular endothelial cell growth factor/vascular permeability factor. Am J Respir Cell Mol Biol 2000; 23: 662-669.
31. Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC. Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 2001; 184: 393-399.
32. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2003; 168: 633-639.
33. McNamara PS, Flanagan BF, Selby AM, Hart CA, Smyth RL. Pro- and anti-inflammatory responses in respiratory syncytial virus bronchiolitis. Eur Respir J 2004; 23: 106-112.
34. Sheeran P, Jafri H, Carubelli C, et al. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J 1999; 18: 115-122.
35. Carpenter TC, Stenmark KR. Endothelin receptor blockade decreases lung water in young rats exposed to viral infection and hypoxia. Am J Physiol Lung Cell Mol Physiol 2000; 279: L547-L554.
36. + channels in respiratory epithelia. Proc Natl Acad Sci USA 2000; 97: 10282-10287.
37. Towne JE, Harrod KS, Krane CM, Menon AG. Decreased expression of aquaporin (AQP)1 and AQP5 in mouse lung after acute viral infection. Am J Respir Cell Mol Biol 2000; 22: 34-44.
38. +-ATPase function by hypoxia in rats. J Appl Physiol 1999; 87: 962-968.
39. Carpenter TC, Schomberg S, Nichols C, Stenmark KR, Weil JV. Hypoxia reversibly inhibits epithelial sodium transport but does not inhibit lung ENaC or Na-K-ATPase expression. Am J Physiol Lung Cell Mol Physiol 2003; 284: L77-L83.
40. Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am J Respir Crit Care Med 2001; 163: S2-S6.
41. Piedimonte G. The association between respiratory syncytial virus infection and reactive airway disease. Respir Med 2002; 96 (Suppl B): S25-S29.
42. Openshaw PJ, Dean GS, Culley FJ. Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches. Pediatr Infect Dis J 2003; 22 (Suppl): S58-S64; discussion S64-S65.
43. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics 1995; 95: 500-505.
44. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000; 161: 1501-1507.
45. Wang SZ, Forsyth KD. Asthma and respiratory syncytial virus infection in infancy: is there a link? Clin Exp Allergy 1998; 28: 927-935.
46. Openshaw PJ. Potential mechanisms causing delayed effects of respiratory syncytial virus infection. Am J Respir Crit Care Med 2001; 163: S10-S13.
47. Martinez FD. Respiratory syncytial virus bronchiolitis and the pathogenesis of childhood asthma. Pediatr Infect Dis J 2003; 22 (Suppl): S76-S82.
48. Piedimonte G. Contribution of neuroimmune mechanisms to airway inflammation and remodeling during and after respiratory syncytial virus infection. Pediatr Infect Dis J 2003; 22 (Suppl): S66-S74; discussion S74-S75.
49. Welliver RC. Immunology of respiratory syncytial virus infection: eosinophils, cytokines, chemokines and asthma. Pediatr Infect Dis J 2000; 19: 780-783; discussion 784-785; 811-813.
50. Culley FJ, Pollott J, Openshaw PJ. Age at first viral infection determines the pattern of T cell-mediated disease during reinfection in adulthood. J Exp Med 2002; 196: 1381-1386.
51. Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 2004; 5 (Suppl A): S119-S126.
52. Colten HR, Krause JE. Pulmonary inflammation - a balancing act. N Engl J Med 1997; 336: 1094-1097.
53. King KA, Hu C, Rodriguez MM, Romaguera R, Jiang X, Piedimonte G. Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am J Respir Cell Mol Biol 2001; 24: 101-107.
54. Masoli M, Fabian D, Holt S, Beasley R. Global Initiative for Asthma (GINA) Program (2004). The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-478.
55. Piedimonte G, King KA, Holmgren NL, Bertrand PJ, Rodriguez MM, Hirsch RL. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res 2000; 47: 351-356.
56. Simoes EA, Carbonell-Estrany X, Kimpen JJ, et al. Palivizumab use decreases risk of recurrent wheezing in preterm children (Abstract #4772), European Respiratory Society Congress, Glasgow, UK, September 4-8, 2004.